ClinicalTrials.gg
CompletedNCT00530920Updated Jun 6, 2014Results posted

Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients

A Phase 2 interventional study of tipranavir and ritonavir in HIV Infections, sponsored by Boehringer Ingelheim. Completed at 12 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-06-06.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
85
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing tipranavir in HIV Infections — none open to participants now, none under way, none of them phase 3. tipranavir · HIV Infections.

Enrollment
9th of 16
85 · median 151
Started
2007
with 4 others
Phase 2
4 of 16
none open now
Registered
12th of 16
by date
Lead sponsor
11 of 16
Boehringer Ingelheim

Among the 16 studies testing tipranavir in HIV Infections, this one is the 9th largest by enrollment, is one of 5 that started in 2007, is one of 4 in phase 2, and was the 12th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 16 studies testing tipranavir in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About tipranavir

tipranavir: first FDA approval 2005 (APTIVUS), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing tipranavir in HIV Infections as a file.
02

Study summary

The purpose of this study is to identify an optimal dose combination(s) of tipranavir (TPV) and ritonavir (RTV) for antiretroviral treatment naïve HIV-1 infected patients that can be used in pivotal trial by assessing the steady-state pharmacokinetics and short-term efficacy and safety

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in accordance with GCP and local regulatory requirements prior to trial participation.
  • -1 infected men and non-pregnant women who are treatment naïve, with positive serology (EIA) confirmed by Western blot.
  • Age > 18 and \< 65 years.
  • > 200 cells/mm3
  • Viral load (HIV-1 mRNA viral load) > 5,000 copies/mL.
  • Ability to swallow multiple large capsules without difficulty.
  • Acceptable laboratory values that indicate adequate baseline organ function at screening visit.
  • Laboratory values are considered to be acceptable if the severity of any parameter is = \< Grade 2, based on the DAIDS/ACTG Grading Scale (see Appendix 10.2).
  • Acceptable medical history, physical examination, and 12-lead at screening
  • Willingness to abstain from the following starting 2 weeks prior to administration of any study medication and up until the end of the study:

    o Grapefruit or grapefruit juice, Seville oranges, St. John's Wort, and Milk Thistle.

  • Willingness to abstain from alcohol 3 days prior to administration of any study medication up to the end of the study.
  • Willingness to abstain from the following starting 3 days prior to PK sampling:

    o Garlic supplements and methylxanthine containing foods or drinks (including coffee, tea, cola, energy drinks, chocolate, etc.).

  • Willingness to abstain from over-the-counter herbal medications for the duration of the study.
  • Willingness to abstain from any over the counter medication 7 days prior to administration of any study medication (including vitamins, minerals, dietary supplements and antacids) during the study until completion of the post study assessments.

Exclusion criteria

Exclusion Criteria:

  • Female patients of who:

    • Have positive serum pregnancy test.
    • Have not been using a barrier method of for at least 3 months prior to participation in the study.
    • Are not willing to use a reliable method of barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during and 60 days after completion/termination of the trial.
    • Are breast-feeding.
  • Suspected or documented seroconversion within last 6 months
  • Participation in another trial with an medicine within 2 months prior to Day 0 of this study.
  • Use of any pharmacological contraceptive (including oral, patch or injectable contraceptives) within 1 month prior to Day 0 and for the duration of the study.
  • Use of hormone replacement therapy within 1 month prior to Day 0 and anytime during the study.
  • History of acute illness within 30 days prior to Day 0.
  • Have evidence of active or acute or .
  • Alcohol or substance abuse within 1 year prior to screening or during the study.
  • Patients with a history of any illness or allergy that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering TPV.
  • Patients who have taken (within 7 days prior to Day 0) any over-the-counter or prescription medication that, in the opinion of the investigator in consultation with the BI clinical monitor, might interfere with absorption, distribution, or metabolism of the study medications.
  • Known to any ingredients of the test drug.
  • Inability to adhere to the protocol.
  • Genotypic resistance to tipranavir (defined as a TPV mutation score > 4).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Intervention model
Parallel assignment
Enrollment
85 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Viral Load (log10 Copies/mL) Change From Baseline (Last Observation Carried Forward (LOCF))

    Time frame: Baseline (Day 0) to Final (Day 14)

Secondary outcomes

  1. Apparent Oral Clearance I(Cl/F) of Tipranavir

    Tipranavir pharmacokinetics - Clearance (CL) is defined as the dose of a drug divided by the area-under-the-concentration-time curve (AUC), ie. CL = Dose / AUC. For extravascu-lar models the fraction of dose absorbed cannot be estimated, therefore "clear-ance" for these models is actually Cl/F where F is the fraction of the drug dose which is absorbed.

    Time frame: Final (Day 14)

  2. Area Under the Curve(AUC) of Tipranavir 24 h for Once Daily (QD) and AUC 12 h for Twice Daily (BID)

    Tipranavir (TPV) pharmacokinetics

    Time frame: Final (Day 13 for QD, Day 14 for BID)

  3. Concentration-24 Hour (hr) Post Dose of Tipranavir - (Cp 24 h for QD and 12 hr Post Dose (CP 12h) for BID

    TPV pharmacokinetics

    Time frame: Final (Day 13 for QD, Day 14 for BID)

  4. Trough Concentration (Cmin) of Tipranavir

    TPV pharmacokinetics

    Time frame: Final (Day 13 for QD, Day 14 for BID)

  5. Maximum Concentration (Cmax) of Tipranavir

    TPV pharmacokinetics

    Time frame: Final (Day 13 for QD, Day 14 for BID)

  6. Volume of Distribution (V/F) of Tipranavir

    Tipranavir pharmacokinetics

    Time frame: Final (Day 14)

  7. Terminal Half-Life (t1/2) of Tipranavir

    Tipranavir pharmacokinetics

    Time frame: Final (Day 14)

  8. Time to Cmax (Tmax) of Tipranavir

    Tipranavir pharmacokinetics

    Time frame: Final (Day 14)

  9. AUC 24 of Ritonavir for QD and AUC 12 of Ritonavir for BID

    Ritonavir pharmacokinetics

    Time frame: Final (Day 13 for QD, Day 14 for BID)

  10. Cp 24 h of Ritonavir for QD and CP 12 h of Ritonavir for BID

    Ritonavir pharmacokinetics

    Time frame: Final (Day 13 for QD, Day 14 for BID)

  11. Apparent Oral Clearance I(Cl/F) of Ritonavir

    Ritonavir pharmacokinetics

    Time frame: Final (Day 13 for QD, Day 14 for BID)

  12. Volume of Distribution (V/F) of Ritonavir

    Ritonavir pharmacokinetics

    Time frame: Final (Day 14)

  13. Terminal Half-Life (t1/2) of Ritonavir

    Ritonavir pharmacokinetics

    Time frame: Final (Day 14)

  14. Tmax of Ritonavir

    Ritonavir pharmacokinetics

    Time frame: Final (Day 14)

  15. Cmax of Ritonavir

    Ritonavir pharmacokinetics

    Time frame: Visits baseline, 5, 7, 9 and 13 or 14

  16. Clinical Abnormal Findings in Laboratory and Physical Examination

    Time frame: Screening through the end of the study (14 days)

07

Results

Posted Jul 8, 2009

Participant flow

Participant flow — Overall Study
MilestoneTipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily
Started302728
Completed302524
Not completed024
Withdrew: Randomized but not treated020
Withdrew: Adverse event003
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryViral Load (log10 Copies/mL) Change From Baseline (Last Observation Carried Forward (LOCF))
Time frame:
Baseline (Day 0) to Final (Day 14)
Reported as:
Median · Log10 copies/mL
Viral Load (log10 Copies/mL) Change From Baseline (Last Observation Carried Forward (LOCF))
Log10 copies/mLTipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily
Viral Load (log10 Copies/mL) Change From Baseline (Last Observation Carried Forward (LOCF))-1.43 (-1.66 to -1.24)-1.55 (-1.70 to -1.37)-1.47 (-1.66 to -1.09)
Statistical analysis
  • Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily · Wilcoxon (Mann-Whitney) · p = 0.997 · Median difference (final values): -1.43
  • Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily · Wilcoxon (Mann-Whitney) · p = 1 · Median difference (final values): -1.55
  • Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily · Wilcoxon (Mann-Whitney) · p = 0.998 · Median difference (final values): -1.47
SecondaryApparent Oral Clearance I(Cl/F) of Tipranavir

Tipranavir pharmacokinetics - Clearance (CL) is defined as the dose of a drug divided by the area-under-the-concentration-time curve (AUC), ie. CL = Dose / AUC. For extravascu-lar models the fraction of dose absorbed cannot be estimated, therefore "clear-ance" for these models is actually Cl/F where F is the fraction of the drug dose which is absorbed.

Time frame:
Final (Day 14)
Reported as:
Geometric mean · L/h
Apparent Oral Clearance I(Cl/F) of Tipranavir
L/hTipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily
Apparent Oral Clearance I(Cl/F) of Tipranavir1.45 ± 26.791.43 ± 26.771.57 ± 35.40
SecondaryArea Under the Curve(AUC) of Tipranavir 24 h for Once Daily (QD) and AUC 12 h for Twice Daily (BID)

Tipranavir (TPV) pharmacokinetics

Time frame:
Final (Day 13 for QD, Day 14 for BID)
Reported as:
Geometric mean · h*uM
Area Under the Curve(AUC) of Tipranavir 24 h for Once Daily (QD) and AUC 12 h for Twice Daily (BID)
h*uMTipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily
Area Under the Curve(AUC) of Tipranavir 24 h for Once Daily (QD) and AUC 12 h for Twice Daily (BID)571.3 ± 27.3289.3 ± 26.8538.2 ± 36.4
SecondaryConcentration-24 Hour (hr) Post Dose of Tipranavir - (Cp 24 h for QD and 12 hr Post Dose (CP 12h) for BID

TPV pharmacokinetics

Time frame:
Final (Day 13 for QD, Day 14 for BID)
Reported as:
Geometric mean · uM
Concentration-24 Hour (hr) Post Dose of Tipranavir - (Cp 24 h for QD and 12 hr Post Dose (CP 12h) for BID
uMTipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily
Concentration-24 Hour (hr) Post Dose of Tipranavir - (Cp 24 h for QD and 12 hr Post Dose (CP 12h) for BID3.26 ± 92.410.27 ± 49.417.75 ± 71.7
SecondaryTrough Concentration (Cmin) of Tipranavir

TPV pharmacokinetics

Time frame:
Final (Day 13 for QD, Day 14 for BID)
Reported as:
Geometric mean · uM
Trough Concentration (Cmin) of Tipranavir
uMTipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily
Trough Concentration (Cmin) of Tipranavir2.8 ± 106.812.73 ± 53.121.26 ± 86.8
SecondaryMaximum Concentration (Cmax) of Tipranavir

TPV pharmacokinetics

Time frame:
Final (Day 13 for QD, Day 14 for BID)
Reported as:
Geometric mean · uM
Maximum Concentration (Cmax) of Tipranavir
uMTipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily
Maximum Concentration (Cmax) of Tipranavir54.64 ± 20.236.98 ± 19.969.66 ± 26.5
SecondaryVolume of Distribution (V/F) of Tipranavir

Tipranavir pharmacokinetics

Time frame:
Final (Day 14)
Reported as:
Geometric mean · L
Volume of Distribution (V/F) of Tipranavir
LTipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily
Volume of Distribution (V/F) of Tipranavir10.02 ± 14.339.33 ± 9.179.39 ± 12.34
SecondaryTerminal Half-Life (t1/2) of Tipranavir

Tipranavir pharmacokinetics

Time frame:
Final (Day 14)
Reported as:
Geometric mean · h
Terminal Half-Life (t1/2) of Tipranavir
hTipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily
Terminal Half-Life (t1/2) of Tipranavir4.79 ± 26.34.51 ± 22.44.14 ± 33.6
SecondaryTime to Cmax (Tmax) of Tipranavir

Tipranavir pharmacokinetics

Time frame:
Final (Day 14)
Reported as:
Geometric mean · h
Time to Cmax (Tmax) of Tipranavir
hTipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily
Time to Cmax (Tmax) of Tipranavir3.07 ± 14.72.34 ± 15.22.38 ± 16.6
SecondaryAUC 24 of Ritonavir for QD and AUC 12 of Ritonavir for BID

Ritonavir pharmacokinetics

Time frame:
Final (Day 13 for QD, Day 14 for BID)
Reported as:
Geometric mean · h*uM
AUC 24 of Ritonavir for QD and AUC 12 of Ritonavir for BID
h*uMTipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily
AUC 24 of Ritonavir for QD and AUC 12 of Ritonavir for BID5.05 ± 44.02.25 ± 47.01.74 ± 48.9
SecondaryCp 24 h of Ritonavir for QD and CP 12 h of Ritonavir for BID

Ritonavir pharmacokinetics

Time frame:
Final (Day 13 for QD, Day 14 for BID)
Reported as:
Geometric mean · uM
Cp 24 h of Ritonavir for QD and CP 12 h of Ritonavir for BID
uMTipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily
Cp 24 h of Ritonavir for QD and CP 12 h of Ritonavir for BID0.005 ± 206.20.039 ± 134.00.025 ± 129.9
SecondaryApparent Oral Clearance I(Cl/F) of Ritonavir

Ritonavir pharmacokinetics

Time frame:
Final (Day 13 for QD, Day 14 for BID)
Reported as:
Geometric mean · L/h
Apparent Oral Clearance I(Cl/F) of Ritonavir
L/hTipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily
Apparent Oral Clearance I(Cl/F) of Ritonavir39.6 ± 44.044.4 ± 47.057.4 ± 48.9
SecondaryVolume of Distribution (V/F) of Ritonavir

Ritonavir pharmacokinetics

Time frame:
Final (Day 14)
Reported as:
Geometric mean · L
Volume of Distribution (V/F) of Ritonavir
LTipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily
Volume of Distribution (V/F) of Ritonavir97.5 ± 26.890.8 ± 24.788.9 ± 28.7
SecondaryTerminal Half-Life (t1/2) of Ritonavir

Ritonavir pharmacokinetics

Time frame:
Final (Day 14)
Reported as:
Geometric mean · Hours
Terminal Half-Life (t1/2) of Ritonavir
HoursTipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily
Terminal Half-Life (t1/2) of Ritonavir1.71 ± 45.51.42 ± 59.51.07 ± 56.1
SecondaryTmax of Ritonavir

Ritonavir pharmacokinetics

Time frame:
Final (Day 14)
Reported as:
Geometric mean · h
Tmax of Ritonavir
hTipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily
Tmax of Ritonavir2.84 ± 23.92.33 ± 24.92.05 ± 28.8
SecondaryCmax of Ritonavir

Ritonavir pharmacokinetics

Time frame:
Visits baseline, 5, 7, 9 and 13 or 14
Reported as:
Geometric mean · uM
Cmax of Ritonavir
uMTipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily
Cmax of Ritonavir0.632 ± 32.50.346 ± 30.70.291 ± 34.7
SecondaryClinical Abnormal Findings in Laboratory and Physical Examination
Time frame:
Screening through the end of the study (14 days)
Reported as:
Number · participants
Clinical Abnormal Findings in Laboratory and Physical Examination
participantsTipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily
Alanine aminotransferase (ALT) increased001
Aspartate aminotransferase (AST) increased001

Adverse events

Collected over 14 days, from first treatment until last treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily—0/30 (0%)17/30 (56.7%)
Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily—0/25 (0%)9/25 (36%)
Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily—1/28 (3.6%)15/28 (53.6%)
Most frequent serious events
Most frequent serious events
EventTipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily
Alanine aminotransferase increasedInvestigations0/300/251/28
Aspartate aminotransferase increasetInvestigations0/300/251/28
Most frequent other events
Most frequent other events
EventTipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily
DiarrhoeaGastrointestinal disorders10/303/2511/28
NauseaGastrointestinal disorders3/301/254/28
HeadacheNervous system disorders2/302/254/28
FatigueGeneral disorders1/303/252/28
Abdominal pain upperGastrointestinal disorders3/301/251/28
FlatulenceGastrointestinal disorders0/302/250/28
DizzinessNervous system disorders2/301/252/28
DysgeusiaNervous system disorders2/300/250/28
InsomniaPsychiatric disorders2/300/250/28

Baseline characteristics

Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment

Age, Continuous
Age, Continuous(years)Tipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice DailyTotal
Mean33 ± 7.5436.9 ± 8.0436.4 ± 835.3 ± 7.94
Sex: Female, Male
Sex: Female, Male(Participants)Tipranavir With Ritonavir (TPV/r) 500/200 mg Once DailyTipranavir With Ritonavir (TPV/r) 250/100 mg Twice DailyTipranavir With Ritonavir (TPV/r) 500/100 mg Twice DailyTotal
Female2147
Male28242476
08

Study locations

12 sites
  • 1182.107.49002 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 1182.107.49004 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 1182.107.49003 Boehringer Ingelheim Investigational Site
    Frankfurt/Main, Germany
  • 1182.107.49001 Boehringer Ingelheim Investigational Site
    München, Germany
  • 1182.107.39001 Boehringer Ingelheim Investigational Site
    Antella (fi), Italy
  • 1182.107.39009 Boehringer Ingelheim Investigational Site
    Bari, Italy
  • 1182.107.39007 Boehringer Ingelheim Investigational Site
    Ferrara, Italy
  • 1182.107.39011 Boehringer Ingelheim Investigational Site
    Palermo, Italy
  • 1182.107.34001 Boehringer Ingelheim Investigational Site
    Barcelona, Spain
  • 1182.107.34002 Boehringer Ingelheim Investigational Site
    Barcelona, Spain
  • 1182.107.34003 Boehringer Ingelheim Investigational Site
    L'Hospitalet de Llobregat, Spain
  • 1182.107.34004 Boehringer Ingelheim Investigational Site
    Madrid, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007 and a primary completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2007
First posted
Sep 18, 2007
Start
Oct 2007
Primary completionActual
May 2008
Results first posted
Jul 8, 2009
Last update
Jun 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00530920
First posted
Sep 18, 2007
Start date
Oct 2007
Primary completion
May 2008
Results posted
Jul 8, 2009
Last update
Jun 6, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tipranavir · Ritonavir

Start the discussion